Consistently, a phase II, single-arm study of AZD1775 monotherapy was conducted (NCT02688907) to evaluate anti-Wee1 treatment in relapsed small cell lung cancer patients with MYC family amplification or CDKN2A mutation combined with TP53 mutation. Here, TP53 is linked to small cell lung carcinoma.